Abstract
Background
Clarithromycin is a commonly used macrolide antibiotic. It is known to cause QT prolongation. Medication induced QT prolongation is a major risk factor for the development of torsade de pointes.
Methods
A 79-year-old lady presented with frequent episodes of torsade de pointes following commencement of clarithromycin. This was noted to be in association with a prolongation of the QT interval.
Conclusion
Knowledge of medications which prolong the QT interval is important to minimize the risk of ventricular arrhythmias, which may lead to sudden death. This is essential in patients with a congenitally long QT interval.
This is a preview of subscription content, access via your institution.

References
Makkar R, Fromm B, Steinman R et al (1993) Female gender as a risk factor for torsade de pointes associated with cardiovascular drugs. JAMA 270:2590–2597
Hohnloser SH, Klingenheben T, Singh BN (1994) Amiodarone-associated proarrhythmic effects. A review with special reference to torsades de pointes tachycardia. Ann Intern Med 121:529–535
Kurita T, Ohe T, Marui N, Aihara N, Takaki H, Kamakura S et al (1992) Bradycardia-induced abnormal QT prolongation in patients with complete atrioventricular block with torsade de pointes. Am J Cardiol 69:628–633
Irish Medicines Board, Pharmacovigilance Department (2006) http://www.imb.ie
Gitler B, Berger LS, Buffa SD (1994) Torsades de pointes induced by erythromycin. Chest 105:368–372
Priori SG, Napolitano C, Schwartz PJ (1999) Low penetrance in the long-QT syndrome: clinical impact. Circulation 99:529–533
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hensey, C., Keane, D. Clarithromycin induced torsade de pointes. Ir J Med Sci 177, 67–68 (2008). https://doi.org/10.1007/s11845-007-0057-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11845-007-0057-3
Keywords
- Acquired
- Clarithromycin
- Medication
- Prolongation
- QT interval
- Torsade de pointes